In yesterday’s Wall Street session, DURECT Corporation (NASDAQ:DRRX) shares traded at $3.29, down -33.13% from the previous session.
4 analysts cover DURECT Corporation (NASDAQ:DRRX), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $44.00 and a low of $32.00, we find $34.50. Given the previous closing price of $4.92, this indicates a potential upside of 601.22 percent. DRRX stock price is now -38.96% away from the 50-day moving average and -35.22% away from the 200-day moving average. The market capitalization of the company currently stands at $81.23M.
The stock has received a hold rating from 0 analysts and a buy rating from 4. Brokers who have rated the stock have averaged $36.25 as their price target over the next twelve months.
With the price target of $7, Chardan Capital Markets recently initiated with Buy rating for DURECT Corporation (NASDAQ: DRRX).
In other news, Robertson Judith J., Director bought 9,412 shares of the company’s stock on Aug 19. The stock was bought for $8,000 at an average price of $0.85. Upon completion of the transaction, the Director now directly owns 356,132 shares in the company, valued at $1.17 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 18, Director Robertson Judith J. bought 71,531 shares of the business’s stock. A total of $60,794 was incurred on buying the stock at an average price of $0.85. This leaves the insider owning 346,720 shares of the company worth $1.14 million. Insiders disposed of 3,498 shares of company stock worth roughly $11508.42 over the past 1 year. A total of 0.20% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DRRX stock. A new stake in DURECT Corporation shares was purchased by ARMISTICE CAPITAL, LLC during the first quarter worth $2,007,000. CAPTION MANAGEMENT, LLC invested $543,000 in shares of DRRX during the first quarter. In the first quarter, SIMPLEX TRADING, LLC acquired a new stake in DURECT Corporation valued at approximately $357,000. PRELUDE CAPITAL MANAGEMENT, LLC acquired a new stake in DRRX for approximately $41,000. MARSHALL WACE, LLP purchased a new stake in DRRX valued at around $36,000 in the second quarter. In total, there are 69 active investors with 43.40% ownership of the company’s stock.
During the past 12 months, DURECT Corporation has had a low of $3.16 and a high of $9.70. As of last week, the company has a debt-to-equity ratio of 1.39, a current ratio of 1.20, and a quick ratio of 1.10. The fifty day moving average price for DRRX is $5.3598 and a two-hundred day moving average price translates $5.0679 for the stock.
The latest earnings results from DURECT Corporation (NASDAQ: DRRX) was released for Mar, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$0.47, beating analysts’ expectations of -$0.53 by 0.06. This compares to -$0.48 EPS in the same period last year. The company reported revenue of $2.05 million for the quarter, compared to $1.92 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.26 percent. For the current quarter, analysts expect DRRX to generate $2.94M in revenue.
